ABUS - アルブ―タス・バイオファ―マ (Arbutus Biopharma Corporation) アルブ―タス・バイオファ―マ

 ABUSのチャート


 ABUSの企業情報

symbol ABUS
会社名 Arbutus Biopharma Corp (アルブ―タス・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development which has enabled several clinical trials and has been administered to hundreds of human subjects.   アルブ―タス・バイオファ―マはカナダのバイオ医薬品企業。主に先進リボ核酸(RNA)干渉(RNAi)治療薬の研究開発に取り組み、製薬企業パ―トナ―に脂質ナノ粒子送達技術を提供する。慢性B型肝炎感染の患者に特化し、B型肝炎ウイルス(HBV)による肝臓疾患に対する治療法の発見、開発、商業化に従事する。本社はブリティッシュコロンビア州。   Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
本社所在地 100-8900 Glenlyon Parkway Burnaby British Columbia V5J 5J8 CAN
代表者氏名
代表者役職名
電話番号 +1 604-419-3200
設立年月日 38626
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 130人
url www.arbutusbio.com
nasdaq_url https://www.nasdaq.com/symbol/abus
adr_tso
EBITDA EBITDA(百万ドル) -66.20400
終値(lastsale) 9.11
時価総額(marketcap) 504733154.78
時価総額 時価総額(百万ドル) 332.42580
売上高 売上高(百万ドル) 12.10600
企業価値(EV) 企業価値(EV)(百万ドル) 298.47880
当期純利益 当期純利益(百万ドル) -84.55700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arbutus Biopharma Corp revenues increased from $1.3M to $2.7M. Net loss applicable to common stockholders decreased 48% to $19.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain on investment increase from $0K to $24.9M (income).

 ABUSのテクニカル分析


 ABUSのニュース

   Altimmune Plans To Progress HepTcell But Market Shrugs It Off  2019-04-15
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,…
   Altimmune Plans To Progress HepTcell But Market Shrugs It Off  2019-04-15
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,…
   Altimmune Plans To Progress HepTcell But Market Shrugs It Off  2019-04-15
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,…

 関連キーワード  (医薬品 米国株 アルブ―タス・バイオファ―マ ABUS Arbutus Biopharma Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)